We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

Presepsin Proposed as 'Robust' Biomarker of Early-Onset Sepsis

By LabMedica International staff writers
Posted on 08 Jun 2022
Print article
Image: Presepsin has been proposed as a `robust` biomarker of early-onset sepsis (Photo courtesy of Ian Ingram, BA)
Image: Presepsin has been proposed as a `robust` biomarker of early-onset sepsis (Photo courtesy of Ian Ingram, BA)

Neonatal early-onset sepsis (EOS) is a severe disease, particularly in preterm infants. Timely diagnosis can be challenging owing to unspecific presentation and questionable performance of the common markers of infection.

Presepsin (P-SEP), the newly identified infection biomarker, is a 13 kDa fragment of the N-terminal of soluble CD14 and is released into the blood upon the activation of monocytes in response to infection. The accuracy of presepsin for the diagnosis of neonatal early-onset sepsis has been examined.

Neonatologists at the Careggi University Hospital (Florence, Italy) and their colleagues performed a literature search for studies involving term or preterm infants diagnosed with EOS, which examined presepsin levels (and measured sensitivity/specificity) during workup for suspected cases. Outcomes of interest for both the primary and secondary analysis (either clinical or culture-proven sepsis) were sensitivity, specificity and diagnostic odds ratio.

In all, 12 studies involving 828 newborns (including 460 with EOS and the rest uninfected) met inclusion criteria for the primary analysis. Ten of the studies included a mix of EOS and LOS, four only included infants born at term, two were restricted to preterm infants, and the rest had a mix. Half of the studies were performed in Egypt, while the remaining were conducted in Europe and Asia. The secondary analysis included 23 studies that met the broader criteria and involved 1,866 newborns (including 1,040 newborns with EOS and the rest uninfected), with seven of the trials involving only newborns with EOS.

The investigators reported presepsin accuracy was not associated with gestational age, measurement with chemiluminescence enzyme immunoassay or enzyme-linked immunosorbent assay testing, country where the study was performed, or risk of bias judgment. In the secondary analysis, among 23 studies and 1,866 newborns, accuracy was significantly associated with only test type. In the primary analysis, among 12 studies and 828 newborns of any gestational age, pooled sensitivity and specificity were 0.93 (95% CI, 0.86-0.95) and 0.91 (95% CI, 0.85-0.95), respectively; pooled diagnostic odds ratio was 131.69 (95% CI, 54.93-310.94). Subgroup analysis showed that presepsin specificity was associated with the inclusion of only EOS or all neonatal sepsis.

Chiara Poggi, MD, PhD, a Neonatologist and senior author of the study, said, “EOS diagnosis is a frequent challenge in the neonatal intensive care unit, as clinical signs are equivocal and the common markers of infection, such as C-reactive protein and procalcitonin, physiologically increase during the first 48 hours of life in response to non-infective stimuli.”

The authors concluded that their systematic review and meta-analysis suggest that presepsin was an accurate biomarker of EOS. Clinical trials are warranted to assess its usefulness and safety to reduce early antibiotic exposure, particularly in preterm newborns. The study was published on May 31, 2022 in the journal JAMA Pediatrics.

Related Links:
Careggi University Hospital

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Silver Supplier
iScope Series

Print article


Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Molecular Diagnostics

view channel
Image: The ClarityDX Prostate test can reduce unnecessary prostate biopsies by up to 35% (Photo courtesy of Nanostics)

Innovative Blood Test to Revolutionize Prostate Cancer Detection and Reduce Invasive Biopsies

One in six men will receive a prostate cancer diagnosis during their lives. Thankfully, if caught early, prostate cancer is highly treatable. However, the existing screening process has its limitations.... Read more


view channel
Image: The latest FDA clearance has finally brought HemoScreen to its full potential as a true POC hematology analyzer (Photo courtesy of PixCell)

True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

An innovative 5-part differential Complete Blood Count (CBC) analyzer with direct capillary sampling capability significantly simplifies blood sampling and minimizes the pre-analytical process.... Read more


view channel
Image: On-chip pretreatment and rapid AST based directly on positive blood cultures (Photo courtesy of Liu Yang)

Integrated Solution for Rapid AST Directly From Positive Blood Cultures to Combat Bloodstream Infection

The presence of living bacteria in the bloodstream, known as bacteremia, can lead to serious conditions like bloodstream infections (BSIs) and sepsis, which can often be fatal. Quickly prescribing the... Read more


view channel
Image: The Mitotic Counting algorithm was trained on over 100,000 individual mitosis and across seven scanner models (Photo courtesy of Gestalt Diagnostics)

New AI Algorithm for Use on Eight Types of Cancer Trained on Seven Scanner Models

A new artificial intelligence (AI) algorithm for use on one of the broadest trained environments is now available for commercial or research work. Gestalt Diagnostics (Spokane, WA, USA) has released the... Read more


view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more


view channel
Image: AACC Middle East is a two-day conference that brings the latest in laboratory medicine to the Middle East region (Photo courtesy of ADLM)

AACC Middle East 2023 to Explore Latest Trends in Clinical Pathology and Laboratory Medicine

The AACC Middle East Conference and Exposition will be held by the Association for Diagnostics & Laboratory Medicine (ADLM - formerly AACC, Washington, DC, USA) in partnership with Life Dx (Abu Dhabi,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.